WHO ICTRP trial
A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY, TO INVESTIGATE THE…
EUCTR2006-001488-51-GB · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2006-001488-51-GB |
|---|---|
| Public title | A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY, TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF THE MGLUR5 NEGATIVE ALLOSTERIC MODULATOR ADX10059 IN THE ACUTE TREATMENT OF MIGRAINE |
| Scientific title | A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY, TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF THE MGLUR5 NEGATIVE ALLOSTERIC MODULATOR ADX10059 IN THE ACUTE TREATMENT OF MIGRAINE |
| Primary sponsor | Addex Pharmaceuticals S.A. |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Germany;United Kingdom |
| Conditions | Migraine with or without aura MedDRA version: 8.1 Level: PT Classification code 10027599 |
| Interventions | Product Name: ADX10059 Product Code: ADX10059 Pharmaceutical Form: Capsule, hard Current Sponsor code: ADX10059 Other descriptive name: (2-(3-Fluorophenylethynyl)-4,6-dimethyl-pyridin-3-yl)amine citrate Concentration unit: mg milligram(s)… |
| Registration date | Sep 20, 2006 |
| Target size | 165 |
| Secondary IDs | ADX10059-201;2006-001488-51-DE |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: